Early Reimbursement Challenges Loom for Lumos Diagnostics’ FebriDx US Launch

Encouraging Early Reimbursement Signals

Lumos Diagnostics (ASX:LDX) has revealed promising early data on reimbursement for its rapid respiratory test FebriDx in the US market, where over 90% of submitted claims are being paid. Notably, the average payment per test is running above the Medicare fee schedule rate of US$41.38, a key benchmark for providers and payers. While the dataset remains preliminary and statistically immature, these early indicators suggest FebriDx is gaining traction among urgent and primary care providers seeking both clinical confidence and economic viability.

The reimbursement progress follows the pivotal FDA CLIA waiver clearance secured in March 2026, which dramatically expanded FebriDx’s addressable market to over 300,000 US healthcare locations. This regulatory milestone unlocked a potential US$1 billion-plus market opportunity, roughly 15 times larger than the prior moderate-complexity classification, positioning Lumos to scale rapidly across diverse care settings.

Expanding Footprint in Urgent Care Networks

Commercial rollout is steadily advancing with FebriDx now in routine use at 44 WellStreet urgent care clinics, part of a network of approximately 165 locations. This early adoption provides a critical reference point for Lumos as it deepens engagement with urgent care operators. The company is also progressing eight additional pilot sites operated by new urgent care chains, reflecting favourable evaluation and implementation stages. This expansion effort is integral to Lumos’ strategy of building a broad installed base ahead of the 2027/28 US flu season, a period expected to drive peak respiratory testing volumes.

These developments build on Lumos’ recent commercial momentum, including a US$1.3 million FebriDx order following FDA clearance, which validated the test’s commercial potential in urgent care and primary care settings. The company’s efforts to broaden its sales pipeline across the US market continue to gain traction, underscoring the growing interest in rapid point-of-care diagnostics.

Strategic Foundations for Next Flu Season

With respiratory infections typically dipping during US spring and summer, Lumos is leveraging this period to solidify market awareness, onboard customers, and refine reimbursement pathways. The company is actively supporting providers with education and claims optimisation to ensure smooth integration of FebriDx into routine clinical workflows. This groundwork is critical as Lumos prepares for the next flu season, when demand for rapid respiratory testing is expected to surge.

Lumos CEO Doug Ward highlighted the importance of these early reimbursement signals, stating they support the view that FebriDx can be embedded into routine workflows across urgent and primary care. This aligns with the company’s broader vision to empower healthcare professionals with rapid, actionable diagnostics that reduce unnecessary antibiotic prescribing.

Broader Clinical and Market Progress

The rollout update complements Lumos’ ongoing clinical advancements, including a BARDA-funded paediatric FebriDx study that recently hit a 250-patient milestone, unlocking US$670,000 in milestone payments. This trial supports regulatory submissions to expand FebriDx use in children aged 2-12 years, potentially broadening the test’s market reach further. The company’s FDA CLIA waiver clearance and milestone payments exceeding US$6 million have underpinned a 37% revenue jump in Q3 FY26, driven by a 243% increase in product sales, reflecting strong commercial momentum.

These interconnected developments paint a picture of a company methodically building both clinical validation and commercial infrastructure. As Lumos navigates the complexities of US healthcare reimbursement and market penetration, the early reimbursement success at urgent care sites offers a tangible sign of progress. However, the seasonal lull in respiratory testing volumes means that broader adoption and statistically significant reimbursement data will likely emerge closer to the next flu season.